Yes. Clinical trials need to include people from different backgrounds impacted by the disease. That is key to us finding out if a new medicine or treatment works. Your unique health experiences are incredibly important and can help move medical innovations forward.
Is there a place for me in a clinical trial?
Yes. Clinical trials need to include people from different backgrounds impacted by the disease. That is key to us finding out if a new medicine or treatment works. Your unique health experiences are incredibly important and can help move medical innovations forward.
Representative research in clinical trials
Representative research is good science. It's part of Johnson and Johnson's commitment to putting patients first and developing safe treatments that work and are accessible to more patients around the world.
Everyone needs medicines that work for them. For a new medicine to help the people it is meant for, clinical trials need to include representative groups of patients with the disease. Making sure that clinical trials are designed with those participants in mind helps us better understand how medicine affects people differently.
Advancing representative research
Connecting patients to clinical trials.
Despite the importance of clinical trials, understanding how they work, where to find information about them, and how to participate can be confusing. That's why we partner with Community Clinical Navigators (CCNs) who meet patients where they are - at health fairs, community events, and organization activations.
CCNs provide education around clinical trials to patients, caregivers, and community leaders with trusted resources. By opening the door to conversations, CCNs help break down barriers, reduce fear, build confidence in clinical research, so more patients feel empowered about the possible role of clinical research in their health.
CCNs participate in events across the country with plans to expand to more states. All events are open to the public.
After meeting with our Community Clinical Navigators, patients willingness to discuss clinical trials jumped from 49% to 90%.
90%
of patients willing to discuss trials
Note: Data from January to June 2025 showed that initially, only 49% of event participants were willing to discuss clinical trials with their doctor or family. After participating in the CCN-led event, that number rose to 90%, demonstrating that conversations with CCNs can significantly increase a person's willingness to talk with their doctor about clinical trials.
After meeting with our Community Clinical Navigators, patients willingness to discuss clinical trials jumped from 49% to 90%.
Note: Data from January to June 2025 showed that initially, only 49% of event participants were willing to discuss clinical trials with their doctor or family. After participating in the CCN-led event, that number rose to 90%, demonstrating that conversations with CCNs can significantly increase a person's willingness to talk with their doctor about clinical trials.
90%
of patients willing to discuss trials
The VISIBLE Study: A success story in representative research
The VISIBLE study was a groundbreaking, large clinical trial designed to include patients of color with moderate to severe psoriasis. In the past, clinical trials often included a majority of participants with only a narrow range of skin tones, which means that researchers have less information about how treatments work for people with less prevalent skin tones. This study aimed to change that by implementing a more inclusive approach.
The study helped create a psoriasis visual guide for different skin tones
Representation of study participants
The VISIBLE psoriasis study was designed for people of color ensuring participants reflected the population affected by this disease. The study included 213 patients worldwide, with 137 U.S. participants.
The chart below shows the U.S. study participant representation in comparison to the prevalence of psoriasis, or the percent of people living with psoriasis during this time.
VISIBLE study participants
Prevalence of Psoriasis when the study was conducted
VISIBLE study participants
Prevalence of Psoriasis when the study was conducted
